This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, L. Articles by Leong, T. Search for Related Content PubMed PubMed Citation Articles by Lim, L. Articles by Leong, T. Social Bookmarking                            What's this?

Adjuvant Therapy in Gastric Cancer

From the Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, Australia

Address reprint requests to Michael Michael, MD, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia; e-mail: michael.michael{at}petermac.org

Gastric cancer has a poor prognosis. The majority of patients will relapse after definitive surgery, and 5-year survival after surgery remains poor. The role of adjuvant therapy in gastric cancer has been controversial given the lack of significant survival benefit in many randomized studies so far. The results of a large North American study (Gastrointestinal Cancer Intergroup Trial INT 0116) reported that postoperative chemoradiotherapy conferred a survival advantage compared with surgery alone, which has led to the regimen being adopted as a new standard of care. However, controversies still remain regarding surgical technique, the place of more effective and less toxic chemotherapy regimens, and the use of more modern radiation planning techniques to improve treatment delivery and outcome in the adjuvant and neoadjuvant setting. This article reviews the current status of the adjuvant treatment for gastric cancer including discussion on the research directions aimed at optimizing treatment efficacy. Issues such as the identification of patients who are more likely to benefit from adjuvant therapy are also addressed. Further clinical trials are needed to move towards better consensus and standardization of care.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Gondos, F. Bray, T. Hakulinen, H. Brenner, and the EUNICE Survival Working Group Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis Ann. Onc., March 1, 2009; 20(3): 564 - 573. [Abstract] [Full Text] [PDF]

				J. Y. An, T. K. Ha, J. H. Noh, T. S. Sohn, and S. Kim Proposal to Subclassify Stage IV Gastric Cancer Into IVA, IVB, and IVM Arch Surg, January 1, 2009; 144(1): 38 - 45. [Abstract] [Full Text] [PDF]

				N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]

				F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, et al. Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC J Natl Cancer Inst, March 19, 2008; 100(6): 388 - 398. [Abstract] [Full Text] [PDF]

				S. Cascinu, R. Labianca, C. Barone, A. Santoro, C. Carnaghi, A. Cassano, G. D. Beretta, V. Catalano, O. Bertetto, S. Barni, et al. Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial J Natl Cancer Inst, April 18, 2007; 99(8): 601 - 607. [Abstract] [Full Text] [PDF]

				D. W. Gee and D. W. Rattner Management of Gastroesophageal Tumors Oncologist, February 1, 2007; 12(2): 175 - 185. [Abstract] [Full Text] [PDF]